Johnson & Johnson announces collaboration to expand manufacturing capabilities for its COVID-19 vaccine candidate
- Details
- Category: Johnson & Johnson
Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate.
Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed.
Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Anti-SARS-CoV-2 antibody test. The test is designed to help determine if a patient has been exposed to the SARS-CoV-2 virus and if the patient has developed antibodies against SARS-CoV-2.
AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
- Details
- Category: AstraZeneca
AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford.
Gilead announces results from Phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19
- Details
- Category: Gilead
Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course (Odds Ratio: 0.75 [95% CI 0.51 - 1.12] on Day 14).
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
- Details
- Category: Novartis
Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.
Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
- Details
- Category: Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalized patients with "severe" or "critical" respiratory illness caused by COVID-19.
More Pharma News ...
- AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
- Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
- Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
- Boehringer Ingelheim steps up effort with Global Support Program
- AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
- Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries
- Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development